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ABSTRACT

Molecular dynamics (MD) simulation was used to investigate the graphene oxide (GO)
based nanocarriers for the loading, carrying, and release of doxorubicin (DOX), a widely used
anticancer drug. The effects of different parameters, including the pH level of the environment and
the oxidation density of the GO nanosheets, on the drug loading and retention is discussed.
Specifically, the DOX release from the GO nanosheet with pH as the triggering mechanism is
explored. Our results confirm that GO can release DOX molecules at acidic pH levels, reminiscent
of the pH level at the solid tumor site. In addition to the pH level and GO surface oxidation density,
the effect of GO PEGylation on the DOX loading was further studied. PEGylation or modifying
the GO surface by grafting it with poly(ethylene glycol) (PEG), is a common way to improve the
hydrophilicity of the nanoparticles in drug delivery systems. Our results indicate that PEGylation
can modify the drug loading mechanism and the drug distribution on the nanocarrier. Moreover,
the PEGylation effect is a function of the PEG chain length. Finally, the behavior of the DOXloaded GO and PEGylated GO in the presence of Human Serum Albumin (HSA) was explored.
Our results show that while HSA can adsorb certain number of DOX molecules loaded on the GO
nanocarrier, PEGylation significantly improves the DOX retention on the nanocarrier. This effect
is more pronounced as the PEG chain length increases.
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CHAPTER 1 INTRODUCTION
Graphene oxide (GO) has been shown to be a potentially good candidate as a nanocarrier
for the delivery of doxorubicin (DOX) anticancer drug.1–5 In general, an efficient drug delivery
system should be able to load the drug, carry it in the bloodstream, and release it at the action
site.6,7 In this study, we use molecular dynamics (MD) simulation to investigate the performance
of this drug delivery system (DDS) in the processes of loading, carrying, and release of the drug
molecules near the cancerous cells. This study contains four parts which are described below.
In the first part of this study, we focused on the drug loading process under various pH
levels. GO, because of its large surfaces, provides a high loading capacity for drug molecules.1,8,9
However, many parameters may affect the GO drug loading capacity, such as GO oxidation
density or pH level of the medium. Having a clear understanding of the drug loading mechanisms
provides us with the knowledge to design a more efficient drug carrier. In this regard, we tried to
reveal the underlying mechanisms of DOX/GO interactions at the molecular level as a function of
the pH level, as well as the oxidation density of the GO sheet. The interaction of a DOX molecule
with pristine graphene (PG), low-oxidized GO and highly oxidized GO at basic, neutral, and acidic
conditions were studied. Energetics and kinetics of the drug adsorption on PG and GOs are
discussed in detail in this part. Drug-carrier, drug-water, and water-carrier interaction energies
were calculated for all different systems and compared. The drug adsorption sites on PG and GOs
at different pH levels were investigated using relative concentration profiles of the DOX molecule.
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Relative concentration profile of water molecules was computed to explore the effect of
water barrier on the drug adsorption at different pH levels. To investigate the kinetic of drug
adsorption and its transport properties, the diffusion coefficient (D) and adsorption time of DOX
molecule in the different DOX/carrier systems and pH levels were calculated.
In addition to the drug loading capacity of a drug delivery system, drug release rate at a
tumor site is another crucial parameter that can significantly affect the efficiency of a drug delivery
system.7 Many internal and external stimuli have been studied for the triggering of the drug release
from the nanocarrier at the tumor site, including temperature variation, ultrasound vibration,
magnetic field, pH level change, and enzymatic activity.10–13 Among these stimuli, pH as the
triggering mechanism has attracted more attention.13–15 Many studies have demonstrated that the
pH level at tumor site is lower than normal cells.13 Therefore, the acidic environment of the tumor
tissue, in addition to triggering the drug release, can enable the selective targeting of cancerous
cells versus normal cells.
In the second part of this study, we investigated the loading and release of DOX molecules
on the GO nanocarrier surface. The nanocarrier ability to load the drug at pH 7 (the physiological
pH) and release it at pH 5 (the pH level of cancerous cells) was analyzed. We further examined
the interaction energy of the system during the adsorption and release processes.
Another key parameter in designing an efficient drug delivery system, is the ability of the
nanocarrier to carry the drug in the bloodstream for a sufficient amount of time. Long nanocarrier
circulation time is crucial for maximum tumor targeting.13,16,17 Bonding the surface of the
nanocarrier with hydrophilic polymer chains such as polyethylene glycol (PEG) is the most
common way to extend the circulation time.16,18–20 In the third part of the study, equilibration and
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dynamics of DOX loading on PEGylated GO is investigated, and the effect of PEG chain length
on drug adsorption is discussed. To provide a clear understanding of the drug adsorption
mechanism on PEGylated GO, the DOX-nanocarrier interaction energy, the adsorption site, the
drug adsorption time as a function of PEG chain length, as well as the evolution of contact area of
DOX-nanocarrier surface were analyzed.
In the fourth part of the study, the behavior of the drug delivery system in the presence of
Human Serum Albumin (HSA) was explored. The drug/nanocarrier complex needs to be stable in
a biological system. 21 This is more important for the non-covalent bonded drug delivery systems.
When discussing the efficiency of a drug delivery system, a main concern is whether the
nanocarrier can hold on to the drug molecules during intravenous delivery to the tumor site or it
will prematurely release them in the presence of proteins prevalent in the bloodstream. To answer
this question, DOX-loaded GO interactions with HSA were examined. Our objective was to
elucidate the effect of HSA on the stability of the drug delivery system during intravenous delivery.
HSA is selected for this study because it is among the first proteins to be adsorbed onto a substrate
and is usually used as a model to investigate the protein-substrate affinity.22 The following chapters
summarize our findings for each study. Each stand-alone chapter includes a literature review,
methodology, results, discussion, and conclusions.
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CHAPTER 2 MOLECULAR SIMULATION OF PH-DEPENDENT DIFFIUSSION,
LOADING, AND RELEASE OF DOXORUBICIN IN GRAPHENE AND GRAPHENE
OXIDE DRUG DELIVERY SYSTEMS
2.1.Abstract
In this work, the adsorption of doxorubicin (DOX) anticancer drug on pristine graphene
(PG) and graphene oxide (GO) nanocarriers with different surface oxygen densities and in an
aqueous environment with varying pH levels were investigated using molecular dynamics (MD)
simulation. The drug loading and release on the GO nanocarrier was also simulated using the pH
as the controller mechanism. Overall, the DOX/nanocarrier interactions become stronger as the
graphene surface oxygen density increases. While pH has negligible effect on single-molecule
drug adsorption on the GO surfaces at acidic and neutral conditions, significantly stronger
DOX/nanocarrier interactions result for the GO nanosheet with the lower surface oxygen density
(GO-16, with an O/C ratio of 1:6) at basic pH levels. Moreover, the DOX/nanocarrier interactions
are greatly weakened for the GO nanosheet with the higher surface oxygen density (GO-13, with
an O/C ratio of 1:3) at basic conditions. These observations are partly attributed to a more favorable
geometry of the DOX molecule on the GO-16 surface, as opposed to a loosely attached DOX
molecule on the edges of the GO-13 nanosheet. When comparing the adsorption kinetics and
transport properties of the DOX molecule in the different GO systems, the drug diffusion
coefficient increases with decreasing pH (going from basic to neutral to acidic) due to reduced
water-nanocarrier total interactions. The latter observation is an indication of a more facilitated
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transport of the DOX molecule in the aqueous medium towards the nanocarrier surface at lower
pH levels. Finally, we have confirmed the loading and release of DOX molecules on the GO
nanocarrier at neutral (pH =7) and acidic (pH = 5) conditions, respectively. The former signifies
the blood pH level, while the latter is reminiscent of the pH of a tumorous cell. The computational
results presented in this work reveal the underlying mechanisms of DOX loading and release on
PG and GO surfaces, which may be used to design better graphene-based nanocarriers for the DOX
delivery and targeting applications.
2.2.Introduction
Doxorubicin (DOX) (Figure 2-1), which is sold under the trade names Adriamycin®,
Doxil®, Caelyx®, and Myocet®, is an anthracycline antitumor antibiotic used in cancer
chemotherapy.24–27 It is widely prescribed for the treatment of leukemia and cancers of the lung,
breast, and ovaries. 28–31 One of the undesired side effects of DOX is its lethality to healthy cells
surrounding a solid tumor. Targeted drug delivery27 is one effective method to overcome this
problem and may increase the efficiency of DOX in cancer treatment.

Figure 2-1. Molecular structure of doxorubicin (DOX) anticancer drug
5

Polymeric micelles,32,33 dendrimers,34,35 liposomes,34,36 hydrogels,37,38 and nanoparticles
39,40

have been used as potential anticancer drug carriers to minimize the drug side effects and

increase its effectiveness. Recently, the focus of drug carrier research has primarily shifted to
carbon nanotubes (CNTs),39,40 nanodiamonds,41 and graphene oxides (GOs).3,42 GOs are twodimensional one-atom-thick nanosheets with a large surface area that can facilitate drug adsorption
on the their surfaces and edges through mechanisms such as π-π stacking, electrostatic interactions,
and hydrogen bonding. 43 Therefore, the drug loading capacity of GO is typically larger than other
nanoparticle-based carriers. The surface of a GO nanosheet is decorated by oxygen-containing
functional groups, such as epoxy, carboxyl, and hydroxyl.44 These hydrophilic groups improve
the water dispersibility of GO and provide a reaction site for covalent modification of the surface
chemistry.45 They further facilitate hydrogen bonding between the drug and the nanocarrier. Due
to a major contribution of electrostatic interactions and hydrogen bonding to the drug adsorption
on the GO surfaces, the pH of the environment plays a critical role in drug loading and release.
Therefore, pH is a suitable controller for the purpose of drug delivery and targeting. There are
numerous reports published in literature to support this statement. For example, Yang et al. 42 used
spectroscopy and electrochemistry to investigate the interactions of DOX with a GO sheet and
elucidated the effect of pH on the DOX loading and release characteristics. They showed that the
highest loading capacity is at the neutral rather than acidic and basic conditions. They suggested
that the hydrogen bonding interaction is the main reason behind the observed pH-dependent
behavior in the DOX/GO drug delivery system. In addition to the pH of the environment, the GO
surface oxidation density also affects the drug loading and release. However, to our best
knowledge, this variable has not been studied in combination with pH in the past, and the present
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work provides insight in this respect.
Molecular dynamics (MD) simulation is a powerful computational tool that can provide
both qualitative and quantitative information regarding underlying physio-chemical mechanisms
and interactions in drug delivery systems. There are limited published reports on the use of MD
simulation to investigate the DOX adsorption characteristics on various nanocarrier surfaces. For
example, Shan et al.46 studied the DOX interactions with ten different hydrophobically modified
chitosan oligosaccharides (COS), as well as the DOX loading mechanism, using MD simulation.
They reported that π–π interactions in aromatic systems play a major role in the DOX loading
behavior. Moreover, they found a relationship between the structure of the solvent surrounding the
DOX and grafted COS with the DOX-drug carrier interactions. Adnan et al.41 investigated the pHdependent interactions between DOX and faceted nanodiamond (ND) nanoparticle carriers using
MD simulation. They showed that the solvent pH acts as an adsorption controller and that DOX
molecules adsorb on the ND surfaces at high pH levels. Wang et al.47 investigated a graphenebased drug delivery system for DOX and three other anticancer drugs, i.e., chlorin e6 (Ce6), MTX,
and SN38. They specifically focused on the effect of graphene sheet size on the drug diffusion and
adsorption on the pristine graphene (PG), GO, and polyethylene glycol-functionalized GO (GOPEG) in vacuum. They conclude that the drug adsorption is more favorable when the drug
molecules and graphene nanosheets become comparable in size. Moreover, the drug molecules
interact more strongly with the GO-PEG carrier than with the PG sheets, which highlights the
advantages of functionalization in improving the stability of graphene-based drug delivery
systems.
Previous research has not adequately explained the underlying mechanism of DOX
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adsorption on graphene-based nanocarriers in aqueous medium at different pH levels. In this
computational study, we quantify the DOX interactions with the PG and GO nanosheets and
choose the GO surface oxidation density and the pH level of the aqueous medium as variables of
interest. The results of this study can be used to design suitable DOX/GO drug delivery systems
with desirable pH-induced drug release characteristics. Moreover, we anticipate that GO could be
used as a potential nanocarrier for the delivery of other anticancer drugs, such as camptothecin and
paclitaxel.
2.3.Computational Method
2.3.1. Molecular Models and Initial Structures
Models of DOX and graphene sheets were created in BIOVIA Materials Studio® (V8.0).
We used finite PG and GO sheets in the dimensions of 20´20 Å2 for simulations involving a single
drug molecule (designated as SIM-1), and 44´41 Å2 for those involving multiple drug molecules
(SIM-2). To create the GO sheets, we randomly decorated the graphene surfaces with hydroxyl
and epoxide groups.48–50 We also added carboxylic acid functions to the edges of the graphene
sheets.51,52 The final oxygen to carbon (O/C) ratios obtained for the GO sheets were 1:6 (designated
as GO-16) and 1:3 (GO-13).
For SIM-1, the graphene sheets were placed at a distance of 10 Å from the bottom of a
three-dimensional (3D) periodic simulation cell of size 40´40´40 Å3, while a DOX molecule was
placed on the top center of the sheet and about 20 Å away from it. These procedures were followed
for each of the DOX/PG and DOX/GO combinations. For SIM-2, only the larger GO-16 sheet was
placed in the middle of a simulation cell of size 60´60´50 Å3, while 24 DOX molecules were
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placed on both sides of the sheet and at an equal distance of ~15 Å from it. In SIM-1, our objective
was to characterize the DOX/PG and DOX/GO interactions and geometries in an aqueous medium
under the influence of varying pH conditions, while in SIM-2, our purpose was to investigate the
loading and release mechanisms of the drug under controlled pH conditions. Next, water molecules
were packed around the drug and nanocarrier molecules at a target temperature of 298 K to achieve
a target density of ~1.2 g/cm3 for both SIM-1 and SIM-2. During the molecular packing process,
the energy of the systems was minimized. Once the packed systems were created, the x, y, and z
coordinates of all graphene sheet carbon atoms were fixed. Also, the charges on the PG sheets
were set to zero based on the common computational practice.53 However, the charges on the GO
sheets were calculated using the “QEq” charge equilibration method54 in Materials Studio. This
method, which is based on accurate ab initio calculations, is widely used in MD simulations to
predict charges for polymers, ceramics, carbon nanomaterials, and biological systems.48,54,55 In the
“QEq” method, the charges are calculated at each dynamic step. The structure files for the GO
sheets, including their atomic charges, are provided in the Supplementary Materials section. There
are also reports on the use of other charge equilibration methods for the GO sheet.50
A snapshot of the initial energy-minimized single-DOX/GO-13 system is shown in Fig. 2a.
In Figs. 2b and 2c, the initial and final snapshots of the multiple-DOX/GO-16 system at pH = 7
(equivalent to the initial snapshot of the system at pH = 5) are illustrated.
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(a)

(c)

(b)

Figure 2.2. Snapshots of the initial structure of the DOX/GO-13/water system (single
interacting DOX molecule) (a), as well as the initial (b) and final (c) structures of the DOX/GOc)
b) interacting DOX molecules) at pH = 7.
16/water system (multiple

To create various pH levels for the DOX/graphene systems, the technique proposed by
Adnan et al.41 for the constant-pH MD simulation (CpHMD) was utilized in this work. The charged
states of the GO sheets and the DOX molecule(s) are calculated based on their pKa values. Overall,
the pKa value of a GO sheet depends on the pKa values of its functional groups. Knowing the pKa
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values of the carboxyl (–COOH) and hydroxyl (–OH) groups (6.6 and 9.0, respectively56), the
number of deprotonated sites of the GO sheets are calculated using the following formula:41

Ndeprotonated = 1

10pKa pH
N total
1 + 10pKa pH
,

2.1

where Ndeprotonated is the number of deprotonated sites and Ntotal is the number of ionizable
functional groups. For instance, if there are 20 carboxylic acid functions on the GO sheet, 17 of
them would be deprotonated at pH = 5. The protonation of the DOX molecule is investigated at
each pH level using its pKa value, which is 8.3.41 DOX is protonated at a pH level lower than 8.3
and is in its natural state at a pH level higher than 8.3.
In SIM-1, the DOX/GO systems were investigated at acidic (pH = 1-5), neutral (pH = 7),
and basic (pH = 9-14) levels. These systems are designated as GO-16-Acidic, GO-16-Neutral, GO16-Basic, etc. For the DOX/PG system, the pH level is 1-8 and this system is designated simply
as PG.
In SIM-2, the drug loading and release are investigated at pH = 7 and pH = 5, respectively.
The charged sites on the GO sheets were determined using Eq. 1, while the number of protonated
DOX molecules was calculated using the following formula41:

N protonated =

10pKa pH
N total
1 + 10pKa pH

(2.2

In Table 2.1, a summary of the different systems for SIM-1 and SIM-2 are given.
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Table 2-1 Details of the DOX/nanocarrier systems and their simulations. The fraction of
charged sites for different systems to achieve different pH levels are also given.

System

Tim
ea
(ns)

Number of Molecules
DOX

Nanocarrier

Water

Fraction of Chargedb Sites
(Ncharged/Ntotal)
Nanocarrier
DOX
-COOH
-OH
1/1
-

DOX/PG
3.0
1
1
2410
DOX/GO-162.5
1
1
2375
1/1
0/6
0/10
Acidic
DOX/GO-163.0
1
1
2376
1/1
5/6
0/10
Neutral
DOX/GO-16-Basic
3.0
1
1
2376
0/1
6/6
10/10
DOX/GO-132.5
1
1
2345
1/1
0/10
0/20
Acidic
DOX/GO-131.5
1
1
2345
1/1
7/10
0/20
Neutral
DOX/GO-13-Basic
2.5
1
1
2345
0/1
10/10
20/20
DOX/GO-16-pH7
1.0
24
1
5751 23/24
14/20
0/40
(Loading)
DOX/GO-16-pH5
1.5
24
1
5751 24/24
0/20
0/40
(Release)
a
Total simulation time.
b
For DOX, charged means protonated, while for –COOH and –OH, it means deprotonated.

2.3.2. Simulation Details
All MD simulations in this work were run in Materials Studio using the COMPASS II force
field (an extension of COMPASS force field57). This universal force field is commonly used in the
simulation of biomolecule/nanoparticle interactions.58,59 The simulations were performed using
an NVT ensemble with 1 fs time step for a total simulation time of 1.0-3.0 ns, depending on the
system (Table 1), until molecular adsorption was established. In all simulations, the temperature
was kept constant at 310 K (normal body temperature) using a Nosé-Hoover thermostat60,61 with
a decay constant of 0.1 ps. A cut-off distance of 12 Å was used for short-range interactions. The
long-range electrostatic interactions were calculated using the particle mesh Ewald method.62
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Every 500 fs, the trajectories and the energy components of the system were output and analyzed
to calculate various interaction energies using the following formula63:

Eint = Esys

( E1 + E2 )

2.3

where Eint is the interaction energy, Esys is the total system energy (DOX + nanocarrier,
water + DOX, or water + nanocarrier), and E1 and E2 are the energies of the individual
components in the DOX-nanocarrier, water-DOX, and water-nanocarrier pairs. The final
equilibrium interaction energy was calculated by averaging the intermediate interaction energies
of the pairs during the last 300 ps of the simulations. The number of hydrogen bonds (H-bonds)
formed between different pairs were also calculated by averaging the intermediate H-bonds during
the last 100 ps of the simulations. It has to be mentioned that while the calculation of the free
energy of binding for a biomolecule on a graphene surface using the potential of mean force (PMF)
is used in various studies,64 we preferred the method of calculating the interaction energy, since
our objective was to determine the drug adsorption site on the GO sheets. By using the PMF
method, we would have put a restriction on the movement of the drug molecule to a specific site
on the GO sheet, which would not provide us with information on the true drug adsorption
mechanism. Indeed, the interaction energy method has been used in the MD simulation of
biomolecular adsorption on various substrates.65–67
Relative concentration profiles were generated in this work for the DOX functional groups
(aromatic, amine, and glycolyl in Figure 2-1) as a function of distance from the PG and GO
surfaces. The dimensionless relative concentration (RC) of a set of atoms within a DOX molecule
contained in any given “bin” is defined as68:
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RC =

2.4

N bin Vtotal
×
Vbin N total

where N bin is the number of atoms in the bin, Vbin is the bin volume, N total is the total number of
the given set of atoms in the system, and Vtot is the total system volume in the simulation cell. In
this study, the simulation cell was divided into 100 bins parallel to the xy-plane (z-direction). The
relative concentration profiles were averaged for the final 500 ps of the simulations.
To calculate the diffusion coefficient, we used Einstein’s definition of the correlation function
of atomic position r :69,70
D=

1
d
× lim
t
6
dt

r (t ) r (0)

2

where t is the simulation time. The mean-square displacement (MSD),

2.5
r (t ) r ( 0)

2

, is

calculated on the basis of the time-series of all atomic positions.
2.4.Results and Discussion
2.4.1. Single-Molecule Drug/Nanocarrier Systems (SIM-1)
1.1.1.1.

Energetics and Geometries
The interaction energies of the DOX-nanocarrier, water-DOX, and water-nanocarrier

systems at different pH levels are shown in Figure 2.3. In this figure, the van der Waals (vdW) and
electrostatic contributions to the total interaction energies are also given separately. Since the
charges on the PG surface were set to zero, there are no electrostatic interaction energies reported
for the PG system.
In Figure 2.3a, the DOX molecule exhibits strong vdW interactions with the PG nanocarrier
14

surface (strongest among all PG and GO combinations), which is attributed to the π-π stacking of
the DOX aromatic group with the PG surface (see the inset of Figure 2.4a). This observation is
confirmed by a larger relative concentration of the DOX aromatic group near the PG surface than
those of the more polar amine and glycolyl groups (Figure. 2.4a). As soon as oxygen-containing
functional groups are added to the graphene surface, electrostatic interactions build up between
the DOX molecule and the GO surfaces, while the vdW interactions weaken. The latter effect is
observed for each of the pH levels with an increase in the O/C ratio. While going from acidic to
neutral pH levels have a negligible effect on the total interaction energies of the DOX/GO
combinations (Figure 2.3a), a significantly stronger interaction is observed for the DOX/GO-16
system at basic pH levels. In contrast, the energy for the DOX/GO-13 system is much lower than
the other systems at these pH levels (Figure. 2.3a). To explain this phenomenon, we need to
compare the adsorption (molecular fixation) sites of the DOX molecule on the graphene surfaces,
as well as the surface geometries of the aromatic, amine, and glycolyl functional groups (Figs. 2.4d
and 2.5c). In DOX/GO-16 system (Figure.2.4d), the drug molecule is adsorbed on the surface and
interacts with it through its favorably oriented aromatic and glycolyl groups, while the amine group
is farther away from the surface. In contrast, DOX is adsorbed on the edge of the graphene sheet
in the DOX/GO-13 system and only interacts loosely with the graphene surface through its amine
functional group. As seen in Figure. 2.3c, the water-nanocarrier interactions is the highest for the
DOX/GO-13 system, suggesting that the water molecules push the drug molecule aside and loosely
solvate it. As a consequence, the drug adsorption on the GO-16 surface is the strongest among all
systems, while it is the weakest in the GO-13 system. In general, the DOX molecule adsorbs on
the edges of the graphene sheets for all systems at acidic, neutral, and basic pH levels, except for
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DOX/PG and DOX/GO-16 at basic pH levels. At these pH levels, water molecules have large
interactions with the DOX molecule, which is in its neutral state (
Table 2-1); therefore, the drug molecule is effectively solvated (Figure 2.3b) and a layer of
water forms between the DOX molecule and the GO surface (Figure 2.6a). In Figure 2.6, the
relative concentration profiles of water on both sides of the GO-16 and GO-13 sheets are shown.
As seen in this figure, the near-surface relative concentration of water is larger for the GO-16Basic (Fig. 6a) and GO-13-Basic (Fig. 6b) systems compared to the others. The presence of a layer
of water around the GO surface at basic pH levels has been reported before.52
In Table 2, the average number of H-bonds for the DOX-nanocarrier, DOX-water, and
water-nanocarrier combinations are given for different DOX/graphene systems at various pH
levels. The average number of H-bonds increases with increasing pH level (going from acidic to
neutral to basic) for both DOX-nanocarrier and water-nanocarrier combinations. The only
exception is for the DOX/GO-16-Basic system, where no H-bonds are formed between the DOX
molecule and the GO surface functional groups. This latter observation is due to the presence of a
water layer in between the drug molecule and the GO nanosheet, as discussed before. The large
number of H-bonds formed between the water molecules and the GO surfaces is the driving force
behind pushing the drug molecule to the GO nanosheet edges, where a smaller number of H-bonds
are formed between the DOX molecule and the –COOH groups present in this region of the GO
nanosheet.
Yang et al.42 report a stronger DOX adsorption on the GO surface at the neutral pH level,
while their experimentally measured DOX-GO interactions at pH = 10 is lower than those at pH
= 7. Their finding is consistent with our results for the GO-13-Basic system. At the carbonyl
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density of our GO-13-Basic (5 mol%), the DOX-GO interactions are lower than those of the GO13-Neutral system. Similarly, at a carbonyl density of 8.1 mol%,71 which is not that different from
ours, the DOX/GO system of Yang et al. shows lower drug adsorption at pH = 10 than that at pH
= 7. However, one significant finding in our simulation is that at lower oxygen densities, the DOXGO interactions are actually much higher at basic pH levels. To our best knowledge, this
phenomenon has not been reported in the literature. In explaining the higher adsorption of the
DOX molecule on the GO surface at the neutral pH level, Yang and his co-workers speculate that
the total number of hydrogen bonds formed between the DOX and the GO surface at pH = 7 are
larger than those formed at pH = 10. In contrast, our observation indicates that the average number
of H-bonds in the DOX/GO-13 system is potentially larger at the basic pH levels than those at the
neutral pH level. The main reason for the observed behavior is the stronger van der Waals and
electrostatic interactions between the DOX molecule and the GO surface (Fig. 3a) and not the
larger number of H-bonds formed between the drug and the GO surface.
As mentioned before, the DOX-GO interactions are basically similar at acidic and neutral
pH levels (Figure 2.3.a). However, Yang et al.42 report higher DOX-GO interactions at the neutral
pH level compared to those at the acidic levels. In calculating the single-molecule drug interaction
energies with the GO surface, we did not see any significant difference between the two pH levels
(Fig. 3a). However, a significant difference is observed for the adsorption of multiple DOX
molecules on a larger GO sheet (SIM-2) at neutral versus acidic pH levels, as will be explained
later in Section 3.2.
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(b)

(a)

(c)
Figure 2.3. van der Waals (vdW), electrostatic, and total interaction energies of the (a) DOXnanocarrier, (b) water-DOX, and (c) water-nanocarrier systems at different pH levels. PG and
GO stand for pristine graphene and graphene oxide, respectively.
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(a)

(b)

(c)

(d)

Figure 2.4. Relative concentration profiles of the glycolyl, amine, and aromatic functional groups
of the DOX molecule adsorbed on the a) pristine graphene (PG) and (b)-(d) graphene oxide (GO)
surfaces at acidic, neutral, and basic pH levels, respectively. The O/C ratio of the GO surfaces is
1:6.
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(a)

(b)

a)

b)

(c)
Figure 2.5. Relative concentration profiles of the glycolyl, amine, and aromatic functional groups
of the DOX molecule adsorbed on the graphene oxide (GO) surfaces at (a) acidic, (b) neutral, and
(c) basic conditions. The O/C ratio of the GO surfaces is 1:3.
c)
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(b)

(a)

Figure 2.6. Relative concentration profiles of water around (a) the GO-16 and (b) GO-13

Table 2-2. Average number of DOX-nanocarrier, DOX-water, and water-nanocarrier hydrogen
bonds (H-bonds) in different DOX/PG and DOX/GO systems.
System
DOX/PG
DOX/GO-16-Acidic
DOX/GO-16-Neutral
DOX/GO-16-Basic
DOX/GO-13-Acidic
DOX/GO-13-Neutral
DOX/GO-13-Basic

DOXNanocarrier
0.00
0.05
0.13
0.00
0.05
0.14
0.48

Average Number of H-bonds
DOXWaterWater
Nanocarrier
16.90
0.00
22.14
73.57
19.19
78.56
19.24
83.19
19.40
143.62
19.81
151.67
22.71
165.80

2.4.2. Kinetics of the Drug Adsorption and Its Transport Properties
In Figure 2.7, the adsorption time plot for the GO-13-Neutral system is shown. The DOX
molecule diffuses towards the GO sheet and adsorbs on its surface approximately 700 ps after the
simulation start. This is evident by a ~65 kcal/mol decrease in the DOX/GO-13 interaction energy.
At still longer simulation times, the DOX molecule is pushed to the edges of the GO surface due
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to large water-nanocarrier interaction energies (Figure. 2.3c) and mainly interacts with the surface
through its amine functional group (Figure. 2.5b). In Table 2-3, the diffusion coefficients of the
DOX molecule in water in different DOX/PG and DOX/GO systems, as well as the molecular
adsorption times, are given. The systems are sorted in the ascending order of the diffusion
coefficient. With decreasing pH level, the diffusion coefficient of the DOX molecule increases.
This observation is attributed to the fact that water-nanocarrier interactions decrease with
decreasing pH level (Figure 2.3c). Also, a slight average reduction is observed for the water-DOX
interactions with decreasing pH levels (Figure 2.3b). These reduced interactions between the DOX
molecule and water, as well as water and nanocarrier, facilitate the DOX diffusion towards the
graphene surface, since it will become easier for the DOX to push the water molecules out of its
way. This hypothesis is confirmed when comparing our results to those of Jiao and Xu72 in another
study. They investigated the diffusion of He, CH4, and CO2 in the presence and absence of water
through two GO nanosheet layers acting as a membrane. They concluded that when water is
present, the gas diffusion through the GO nanosheets is slower due to hydrogen bond formation
between the water molecules and the GO surfaces.
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Figure 2.7. Adsorption of DOX on the GO-13 surface at the neutral pH level

Table 2-3. Diffusion coefficient (D) and average adsorption time of the DOX molecule in
different DOX/PG and DOX/GO systems.
System
DOX/PG
DOX/GO-16-Basic
DOX/GO-16Neutral
DOX/GO-16Acidic
DOX/GO-13-Basic
DOX/GO-13Neutral
DOX/GO-13Acidic

D
(10 cm /s)
1.65
1.22
5

2

1.71

Average
Adsorption Time (ps)
3000
1800
2500

2.08
1.07
1.28
1.98

1500
2500
700
1500

2.5.Loading and Release of DOX on the GO Surface (SIM-2)
To investigate the effect of pH on the DOX loading and release on graphene nanocarrier
surfaces, we performed MD simulations of the DOX/GO-16 system at neutral (pH = 7) and acidic
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(pH = 5) conditions. We purposefully selected this specific DOX/GO system and the pH levels. It
is well-known that in the neighborhood of a cancerous tumor, the local pH is about 5, while the
blood has a neutral pH level. Moreover, the typical O/C ratios reported in the literature for the GO
nanocarriers is ~20%.44 Our GO-16 nanocarrier has an O/C ratio of ~17%, which is very close to
the experimentally measured value. As seen in Fig. 8, the DOX molecules adsorb on the graphene
surface at pH = 7 after ~750 ps from the simulation start. When the pH is decreased to 5, an increase
of ~20 kcal/mol in the interaction energy of the DOX/GO-16 system is observed, which indicates
that the DOX molecules are more loosely adhered to the surface. They further reorient into a more
perpendicular conformation on the surface (see the insets of Figure 2.8). We take these
observations as a criterion for the drug release at the acidic pH levels.
The electrostatic interactions between the DOX and the GO-16 sheet at pH = 7 (-36.61
kcal/mol) are significantly larger than those at pH = 5 (-11.77 kcal /mol), which means there is a
strong drug adsorption on the GO nanosheet at the neutral pH level. While adsorbing on the GO16 surface at pH = 7, the DOX molecules tend to form far more H-bonds between themselves than
with the nanocarrier surface (Table 2-4). The formation of these bonds facilitate molecular
aggregation of DOX on the GO nanosheet. Moreover, these aggregates are primarily concentrated
around the GO edges. At the acidic pH level, the DOX molecules are adsorbed more evenly on the
GO surface (Figure 2.8) and are able to form a larger number of H-bonds with the graphene surface
functional groups than those at the neutral pH level (Table 2-4). Moreover, the DOX-GO van der
Waals interactions at pH = 5 (-12.80 kcal/mol) are larger than those at pH = 7 (-7.60 kcal/mol),
which indicates that the DOX molecules are primarily adsorbed on the GO surface. The average
DOX-DOX H-bonds are also dropped from 13.14 at pH = 7 to 9.00 at pH = 5 (Table 2-4),

24

indicating that the DOX molecules are less aggregated.

Figure 2.8. The loading and release of 24 DOX molecules on the GO-16 surface at pH = 7 and
pH = 5, respectively.

Table 2-4. Average number of DOX-DOX and DOX-nanocarrier hydrogen bonds (H-bonds) in
the DOX/GO-16 system at neutral and acidic pH levels.
System

DOX/GO-16 (pH = 7)
DOX/GO-16 (pH = 5)

Average Number of Hbonds
DOXDOXDOX
Nanocarrier
13.14
4.14
9.00
9.83

2.6.Conclusions
Doxorubicin (DOX) anticancer drug and its delivery and targeting using various
nanocarriers has been a subject of intensive research. While, based on experimental data, the effect
of pH on the drug’s loading and release characteristics has been known for a while, the molecularscale mechanisms associated with these phenomena have remained elusive. Moreover, graphene
oxide (GO) has proven to be an effective nanocarrier for DOX, but the combined effect of the GO
surface oxygen density and pH on the drug-nanocarrier interactions has largely been overlooked.
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In this computational work, the DOX/pristine graphene (PG) and DOX/GO interactions at various
neutral, acidic, and basic pH levels were investigated. We also determined the equilibrium
geometries of the DOX molecule on the graphene surfaces. Moreover, the loading of the drug on
the GO surface at a neutral pH level and the release of the drug at an acidic pH level were
simulated. Overall, the adsorption of the DOX molecule on the graphene surface increases with
increasing graphene surface oxygen density except for the GO surface with the highest O/C ratio
of 1:3 in this work. The effect of pH is negligible at neutral and acidic levels, but a significantly
strong interaction is observed for the DOX/GO combination at lower surface oxygen density (O/C
ratio of 1:6) and basic pH levels. This seemingly unexpected result is due to a more favorable
orientation of the DOX molecule on the GO surface, whereby stronger DOX-GO electrostatic
interactions result. For the other pH levels and graphene surface oxygen densities, the DOX
molecule mainly fixates on the edges of the GO sheet and interacts with the nanocarrier in a more
selective fashion through one or more of its main functional groups (aromatic, amine, and
glycolyl). Our results further indicate that the DOX molecular diffusion rate increases with
decreasing pH levels, mainly because of a reduced water-DOX and water-nanocarrier interactions.
To investigate the DOX loading on the GO surface and its release using pH as the
controlling mechanism, we simulated the adsorption and release of 24 DOX molecules on the GO
surface (O/C ratio of 1:6) at pH = 7 and pH = 5, respectively. Our results confirm the favorable
drug loading at the neutral blood pH level and its release at acidic pH levels of the environment
surrounding a cancerous tumor. The results presented in this work shed light on the molecular
mechanisms of DOX loading and release under the influence of pH and graphene surface oxygen
density. They further aid in the optimal design of DOX delivery and targeting using graphene-
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based nanocarriers.
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CHAPTER 3 CHAPTER 3 MOLECULAR INSIGHTS INTO LOADING DYNAMICS AND
EQUILIBRATION OF DOXORUBICIN ON PEGYLATED GRAPHENE OXIDE
NANOCARRIERS
3.1.Abstract
Molecular dynamics (MD) simulations were performed to investigate the loading dynamics
and equilibration of doxorubicin (DOX) anticancer drug on graphene oxide (GO) and
poly(ethylene glycol) (PEG) decorated GO (PEGylated GO) nanocarriers in an aqueous
environment at normal body temperature (310 K) and physiological pH level of 7.4. Mechanisms
of DOX adsorption on PEGylated GO as a function of PEG chain length was revealed, signifying
a “water barrier” effect in a hydration layer surrounding the nanocarrier. This effect is responsible
for the distribution of the adsorbed drug molecules on the accessible GO surface area, as well as
protruding PEG arms at equilibration. While the total DOX-nanocarrier interaction energy was the
same for the DOX/GO (control), DOX/Sh-PEGylated GO (short PEG chains consisting of 15
monomers), and DOX/L-PEGylated GO (long PEG chains consisting of 30 monomers) within the
margin of error, the PEG-DOX interactions increased with an increase in the PEG chains length,
while the PEG-DOX contact area almost doubled going from the short to long PEG chains. An
increase in the average local water density in the hydration layer, combined with the above
observations, shows that DOX molecules, while technically still adsorbed on the nanocarrier, tend
to interact more with the PEG chains as the PEG chain size increases. Moreover, the DOX-DOX
contact area is smaller in the DOX/GO system, which means the drug molecules are less

28

aggregated in this system. However, the level of DOX aggregation is slightly higher for the
PEGylated GO systems. The computational results in this work shed light on the fact that
increasing the PEG chain length benefits DOX loading on the nanocarrier, something that has
either been overlooked in relevant experimental work or not been investigated because of
experimental limitations. Moreover, a clearer picture is provided for the DOX adsorption and
retention in PEGylated GO drug delivery systems, which would enable the researchers to improve
the drug’s circulation time, as well as its delivery and targeting efficiency.
3.2.Introduction
In the last two decades or so, much research has focused on using nanotechnology for cancer
treatment73–80 and improving the quality of life for cancer patients, including design of nanocarriers
for an efficient tumor-targeted delivery of anticancer drugs.81–90 The main objective in the
nanoparticle-based drug delivery approach has been to design nanocarriers with high loading
capacity for anticancer drugs that would deliver a given drug exclusively to the solid tumor site,
thereby, significantly decreasing its unwanted side effects.89–91 Drug loading on nanocarriers
involves either physical or chemical bonding of the drug molecules to the accessible nanocarrier
surface.92–96 Depending on the drug-nanocarrier bonding mechanism, challenges to the efficient
drug delivery to the tumor site are very different. For example, the chemically-bound drugs on
nanocarriers are more stable in the human body, while the physically-bound drugs (passively
loaded), especially those that are surface-adsorbed on the nanocarriers, may be negatively affected
by interactions with, say, blood components during delivery. These interactions cause premature
drug release into the bloodstream; therefore, a clear understanding of drug-nanocarrier interactions
provides a pivotal role in designing more efficient and robust drug delivery systems.
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Graphene oxide (GO),97 a two-dimensional single-layer carbon sheet decorated with oxygencontaining functional groups, has been shown to be a suitable carrier for the loading of drug
molecules on its large surface and edges through both covalent and noncovalent interactions.98 The
basal plane of the GO sheet facilitates π-π interactions with the drug molecules, while its functional
groups, including hydroxyl, epoxy, and carboxyl groups, promote strong drug-nanocarrier
interactions through electrostatic affinity, as well as hydrogen bonding.99,100 These noncovalent
interactions are widely used in drug delivery applications.92 Moreover, the GO functional groups
provide potential moieties for covalent bonding with the drug molecules.101
In addition to the drug loading capacity of GO, the circulation time of the drug/nanocarrier
complex in the bloodstream102 is another important parameter to consider for an efficient drug
delivery and targeting. The drug-loaded GO nanocarriers deliver the drug molecules to the solid
tumor site by way of enhanced permeability and retention (EPR) effect.13,103,104 Based on this
effect, the leaky vasculature of the tumor site facilitates the extravasation of nanoparticles with
sizes smaller than 100 nm from the bloodstream into the tumors, as well as their retention in the
tumor tissue after penetration.25 A crucial aspect of the EPR effect is its time dependence.105 This
means that, to take full advantage of the EPR effect and maximize the drug targeting efficiency,
the drug-loaded nanocarriers need to remain in the bloodstream for a relatively long period of time
in order for their extravasation into the tumors to be realized.
Decorating the surface of the nanocarrier with chains of a hydrophilic polymer, such as
polyethylene glycol (PEG),106 is the most common way to extend the circulation time of the
drug/nanocarrier complex in the bloodstream.107 Many researchers have published reports on the
use of PEG-decorated GO (PEGylated GO) in biological applications.25,107–110 For example, Miao
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et al.109 investigated the potential use of PEGylated GO as a co-delivery system for chlorin e6
(Ce6) and doxorubicin (DOX). They compared the in vitro cytotoxicity and in vivo safety of GO
versus those of PEGylated GO, reporting that the in vivo safety of PEGylated GO is much higher
than that of GO. Furthermore, the loading efficiency of Ce6 and DOX on PEGylated GO is
reported to be more than 50%. They speculated that their observed high drug loading capacity of
PEGylated GO might be attributed to a large aromatic surface area of these drugs, which facilitates
the π-π and hydrophobic drug-nanocarrier interactions. In another study by Zeng et al.,107 a method
was introduced to obtain stable, dispersed PEGylated GO, which they used to deliver Ce6 as a
photosensitizer. They investigated the effect of PEG chain length on the stability of PEGylated
GO and showed that PEGylated GO with short PEG chains tend to aggregate. On the contrary,
long PEG chains were claimed to provide more stable PEGylated GO solutions. However, they
did not investigate the effect of PEG chain length on drug loading. They further determined the
interactions between Ce6 and PEGylated GO and reported that these interactions were noncovalent
in nature, occurring predominantly between Ce6 and the aromatic portion of the PEGylated GO.
Despite valuable research on the use of PEGylated GO as a nanocarrier for various drug
delivery systems, the effects of PEGylation on the drug adsorption mechanisms are still not clear.
In this study, molecular dynamics (MD) simulation was used to fundamentally investigate the
loading mechanisms of DOX on PEGylated GO as a function of PEG chain length with GO used
as the control nanocarrier. Overall, the objective herein is to reveal the energetic and structural
details of drug adsorption on the nanocarriers under equilibrium and dynamic conditions. The
computational results in this study provide a clearer picture of the drug adsorption and retention in

31

PEGylated GO drug delivery systems toward increasing their circulation time and correspondingly
their delivery and targeting efficiency.
3.3.Computational Details
Structures of finite GO and PEGylated GO sheets, as well as DOX, were built in BIOVIA
Materials Studio (v8.0). To build a GO sheet, the top and bottom surfaces of a pristine graphene
sheet (size: 40×40 Å2) were randomly decorated with hydroxyl (-OH) and epoxide (-O) functional
groups.99,111,112 In addition, carboxylic acid groups (-COOH) were added to the edges of the
sheets47,99,111–113. The carbon-to-epoxide, carbon-to-hydroxyl, and carbon-to-carboxylic acid ratios
were C10O1(OH)1(COOH)0.5. This molecular structure is widely used to represent the GO
structure.113 The protonation states of the functional groups were set according to the pH level of
7.4, which is the physiological pH level. To prepare the PEGylated GO structures, two PEG chains,
containing 15 and 30 monomers, and an amide linkage were made. Six chains of short PEG
(molecular length corresponding to 15 monomers) were covalently attached to the GO sheet (one
on each of the two sheet surfaces) to obtain the short-PEGylated GO (labeled as Sh-PEGylated
GO)47. In each chain, the amide linkage was replaced with a carboxyl group on the GO sheet.107
Longer PEG chains (30 monomers) were also used to model the long-PEGylated GO (LPEGylated GO). The prepared models were geometry-optimized using the Dreiding force field114
and charge-equilibrated using the Gasteiger charges routine113. Next, the equilibrium structures
were exported to the Visual Molecular Dynamics (VMD) software.115 The PEGylated GO
structures were placed in a simulation cell, packed with TIP3P water molecules,116 and an NPT
(constant number atoms, N; constant pressure, P; constant temperature, T) simulation was run for
20 ns at 310 K (normal human body temperature) and 1 atm using the NAMD (v2.12) software
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package117 to equilibrate the PEG chain conformations on the GO sheets. Parameters for GO and
PEGylated GO were extracted from the CHARMM36 force field.118 The same force field
parameters have used by other researchers in the past for similar work, including that of Luo et
al.47 The time step, cut-off distance for long-range interactions, and switch distance for short-range
interactions were 2 fs, 12 Å, and 10 Å, respectively. These same parameters were used for the
subsequent simulations described later in this section.
Next, the equilibrated GO and PEGylated GO structures were used to build three drug delivery
systems, i.e., DOX/GO, DOX/Sh-PEGylated GO, and DOX/L-PEGylated GO. In each system, the
nanocarrier was placed in the middle of a simulation cell surrounded by10 DOX molecules, evenly
placed on both sides of the nanocarrier (five drugs on each side), at an initial distance of 20 Å from
the nanocarrier surface. Next, TIP3P water molecules116 were packed around the drug/nanocarrier
complexes such that the distance between outermost atoms in the drug/nanocarrier complex and
the boundary of the created simulation box was 10 Å. The solvated systems were neutralized by
adding sodium ions to the systems. For illustration purposes, a sample initial structure for the
DOX/Sh-PEGylated system is shown in Figure 3-1. Structural details of the three drug delivery
systems are given in Table 3-1.
Table 3-1. Structural details of the drug delivery systems used in this work
Number of Molecules
Cell Size (Å3)
Nanocarrier DOX Water
DOX/GO
1
10 14,740
75×70×95
DOX/Sh-PEGylated-GO
1
10 14,386
75×70×95
DOX/L-PEGylated-GO
1
10 23,892
93×91×95
System
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Figure 3-1. A sample initial configuration of the solvated DOX/Sh-PEGylated GO system.

All subsequent simulations were run in NAMD (v2.12) software package117 with
CHARMM36 force field.118 This force field has previously been used for the MD simulation of
similar biomolecular systems.47 To sample adequate phase space and obtain a statistical measure
of the variations in the collected data, all simulations were replicated four times, and the results
were both time-averaged and averaged over the four replicates. The following describes the
simulation procedure for all systems:
First, a 1,000-step minimization was performed. Next, an NPT simulation was run at 310 K
and 1 atm for 30 ns. The temperature and pressure were controlled using the Langevin thermostat
and barostat, respectively.119 Electrostatic long-range interactions were computed using the
particle mesh Ewald (PME) method.62 The equilibration criterion for the drug delivery systems
were established based on the plateauing of the number of adsorbed DOX molecules on the
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nanocarriers, root-mean-square deviation (RMSD) of the DOX molecular positions, and GO-DOX
contact area. The calculation methods for these properties are described later in this section, while
the actual data are given in the next section.
The energy components of the systems were saved every 200 ps, where after van der Waals
(vdW), electrostatic, and total GO-DOX and PEG-DOX interaction energies were calculated using
the NAMD energy plugin. The final equilibrium interaction energies were calculated by averaging
over all the intermediate interaction energies of the above pairs during the last 2 ns of all four
replicate simulations.
The radial distribution function (RDF)120 of the DOX molecules around the GO sheets were
determined for all systems by time-averaging the data for the last 2ns of the simulations. The final
average RDF values for each drug/nanocarrier system were calculated based on the averaging of
the data obtained for the four replicates.
The time-dependent number of adsorbed DOX molecules on the GO surface was calculated
based on the following adsorption criterion: each drug molecule that has at least one atom within
a distance of 5 Å from the GO surface is considered an adsorbed drug on the GO surface. This
distance is based on the RDF results at equilibrium for the DOX/GO system, which is discussed
in the next section. Calculations were made every 2 ns of the total simulation time.
In this work, a hydration layer (HL) is defined,121 which surrounds the accessible GO and/or
PEG chains. This layer acts as a barrier to the DOX-GO and DOX-PEG interactions. The average
water density in this hydration layer (

HL )

was calculated by counting the number of oxygen

atoms in the water molecules in a 5-Å layer around the nanocarriers (GO surface and PEG chains)
and dividing this number by the volume of the layer. To calculate the volume of the layer,
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Connolly’s solvent-accessible surface area (SASA)122 of the nanocarrier was computed for four
sublayers, starting at a distance of ~1.4 Å from the nanocarrier surface (vdW radius of water123)
and summing up the sublayer volumes. The first sublayer has a thickness of 0.5 Å, while the
subsequent sublayers are 1-Å thick.
The RMSD of DOX and PEG molecular positions relative to their initial positions were
calculated every 200 ps using the RMSD trajectory tool. The evolution of GO-PEG contact areas
were calculated using SASA. For this purpose, the SASA of GO sheet, PEG chains, and the GOPEG complex were first computed for each frame of the trajectory and next, the GO-PEG contact
area was calculated using the following formula:124

GO - PEG Contact Area =

1
( SASAGO + SASAPEG SASAGO
2

PEG

),

(1)

where SASAGO and SASAPEG are the solvent-accessible surface areas of the GO sheet and PEG
chains, respectively. SASAGO

PEG

is the solvent-accessible surface area of the GO-PEG complex.

The same method was used to calculate the GO-DOX and DOX-PEG contact areas.
To evaluate the DOX aggregation, the time-dependent DOX-DOX contact area was calculated
using the following formula:

DOX - DOX Contact Area ( t ) =

1
SASADOX ( 0 ) SASADOX (t ) ,
2

(2)

where SASADOX ( 0) is initial solvent-accessible surface of the DOX molecules at time zero. In the
initial (non-aggregated) state, all drug molecules are separated and there is no contact area between
them. SASADOX ( t ) is the solvent-accessible surface of DOX molecules at time t.
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3.4.Results and Discussion
Sample equilibrium configurations of the DOX-loaded systems are shown in Figure 3.2. For
clarity, the water molecules are excluded from the illustrations. In the DOX/GO system (Figure
2a), all the GO surface is accessible for the DOX loading, which leads to a uniform equilibrium
DOX adsorption pattern on the nanocarrier with a minimal aggregation of the DOX molecules (a
discussion on the DOX aggregation based on the contact area follows later). In the DOX/ShPEGylated GO system, a reduced accessible GO surface leads to the migration of the DOX
molecules to the edges of the GO sheet upon adsorption, where the majority of DOX molecules
interact with the prevalent carboxylic acid functional groups. Furthermore, an increase in the DOX
aggregation is observed. In this system, a small number of DOX molecules interact with the PEG
chains.
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a)

c)

b)

Figure 3.2. Sample equilibrium configurations of a) DOX/GO, b) DOX/Sh-PEGylated GO, c)
and DOX/L-PEGylated GO after 30 ns of simulation. The DOX molecules (thin) are colored
brown, while the PEG chains (thick) are colored blue.

The van der Waals (vdW), electrostatic, and total GO-DOX and PEG-DOX interaction
energies, as well as the equilibrium contact area for the DOX molecules with the GO surface, PEG
chains, and other DOX molecules (time-averaged over the last 2 ns of the simulations) are given
in Figure 3.3. While the total nanocarrier-DOX interaction energies remain the same (within the
margin of error) for the three DOX/GO, DOX/Sh-PEGylated GO, and DOX/L-PEGylated GO
systems, there is an obvious shift in the contributions of the GO-DOX and PEG-DOX interactions
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to the vdW, electrostatic, and total interaction energies. DOX molecules in the DOX/Sh-PEGylated
GO system tend to interact with the GO surface rather than the PEG chains, which is evident from
the GO-DOX electrostatic interactions in the DOX/Sh-PEGylated GO system being negligible and
the total PEG-DOX interactions being too small in contrast to the corresponding interaction
energies in the DOX/GO system (Figure 3.3b vs 3.3a). This tendency is also confirmed by
comparing the larger GO-DOX to the smaller PEG-DOX contact area in Figure 3.3d. Liao et al.,125
who investigated the encapsulation of DOX molecules within PEGylated poly(amidoamine)
dendrimers have reported a similar behavior. Based on their observation, increasing the
PEGylation density does not change the number of adsorbed drugs appreciably. They speculated
that DOX molecules tend to interact with the hydrophobic parts of the dendrimer carrier rather
than the hydrophilic PEG chains. Notwithstanding their observation, a PEG chain length effect
might be possible, which they overlooked in their investigation. Based on our results, as the PEG
chain length increases in the DOX/L-PEGylated GO system, an increase in the ratio of PEG-DOX
to GO-DOX total interaction energy (Figure 3.3c), as well as the contact area (Figure 3.3d),
signifies a larger tendency for the DOX molecules to be loaded on the PEG chains. These new
results confirm that as the PEG chain length increases, more of the drug molecules interact with
the PEG chains during the drug loading. The same tendency might apply in the drug delivery
system of Liao et al.125 With an increase in the PEG chain length, the DOX-PEG contributions to
the total interaction energy increases up to about 32% for the DOX/L-PEGylated GO system
(Figure 3.3c). This is due to a pronounced reduction of the accessible GO surface area and the
existence of long free PEG chains that are able to trap the DOX molecules in the DOX/L-
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PEGylated GO system. Some of these trapped DOX molecules between the PEG chains are visible
is Figure 2c.

b)

a)

c)
d)
Figure 3.3. a) van der Waals (vdW), b) electrostatic, and c) total interaction energies of the DOX
molecules with the available GO surface and PEG chains in DOX/GO, DOX/Sh-PEGylated GO,
and DOX/L-PEGylated GO systems; d) equilibrium contact area between DOX molecules and
the GO surface, PEG chains, and other DOX molecules obtained by time-averaging the data over
the last 2 ns of the simulations. The total DOX surface area is 7,361 Å2.
The above DOX adsorption behavior can be explained by the effect of a hydration layer121
that is formed around the nanocarrier (the GO surface plus the PEG chains). The relevant data are
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summarized in Table 3-2, where it is evident that PEGylation of the GO effectively causes an
increase in the average water density around the nanocarrier, an effect that further increases with
an increase in the PEG chain length. This means that larger number of water molecules are
available on top of the PEG-covered part of the GO surface. This layer can act as a barrier, leading
to the DOX migration to the uncovered part of the GO surface.
Table 3-2. Average water density in the hydration layer after 1 ns of dynamics simulation
3

HL (g/cm

System

)

DOX/GO

1.297±0.009

DOX/Sh-PEGylated-GO

1.324±0.007

DOX/L-PEGylated GO

1.347±0.039

The average equilibrium distribution of the DOX molecules on the GO and PEGylated GO
surfaces are shown in Figure 3.4. The majority of DOX molecules reside at an average distance of
about 5 Å from the accessible GO surface (ditance at the peak of the RDF curve for the DOX/GO
system). In the Sh-PEGylated GO system, the same average distance is observed for the majority
of DOX molecules from the accessible GO surface, but with less peak intensity. At equilibrium,
the short PEG chains are mostly folded on the free GO surface (Figure 3.2b), causing most of the
DOX interaction with the nanocarrier to be confined to the accesible GO surface. With an increase
in the PEG chain length in the L-PEGylated GO system, the average distance of the majority of
DOX molecules from the accessible GO surface increases to slightly above 10 Å, which signfies
considerable engagement of the DOX molecules with the protruding PEG arms (Figure 3.2c)
through DOX-PEG interactions (Figure 3.3). Gleaing from the RMSD curved for DOX
(Figure 3.5) and PEG molecular positions (Figure 3.6), it is also observed that at long simulation
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times, i.e., >10 ns for the DOX/GO (Figure 3.5a) and >20 ns for DOX/Sh-PEGylated GO systems
(Figure 3.5b), the DOX molecules obtain a stable equilibrium configuration in the
DOX/nanocarrier complex. However, in the L-PEGylated GO system (Figure 3.5c), while the
DOX molecules interact favorably with the PEG chains (Figure 3.3), they are considerably more
mobile around the PEG chains. The PEG chains reach an equilibrium configuration around the GO
surface almost immediately after the start of the simulation (Figure 6), with the short PEG (S-PEG)
chains residing very close to the GO surface (essentially folding on it), and the long PEG (L-PEG)
chains reaching an equilibrium configuration that is reminiscent of mostly protruding PEG chains
(Figures 3.2c and 3.6).

a)
Figure 3.4. Radial distribution function (RDF) of DOX in the different DOX/nanocarrier systems,
obtained by averaging the data over the last 2 ns of simulations and over four replicate systems.
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b)

a)

c)
Figure 3.5. Root-mean square deviation (RMSD) of the DOX molecular positions from the GO
surface as a function of simulation time in a) DOX/GO, b) DOX/Sh-PEGylated GO, and DOX/LPEGylated GO systems. The RMSD plots for each of the four replicates are shown.
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a)
Figure 3.6. Root-mean square deviation (RMSD) of the PEG molecular positions from the GO
surface as a function of simulation time in the PEGylated systems.
To better understand the dynamics of DOX adsorption on the DOX/nanocarrier systems, the
number of adsorbed drug molecules on the accessible GO surface was generated as a function of
simulation time (Figure 3.7a). On average, the DOX adsorption rate on the nanocarriers follows
the following order: DOX/GO > DOX/Sh-PEGylated GO > DOX/L-PEGylated GO, with the
DOX/GO system showing the fastest equilibration of the DOX loading on the accessible GO
surface (>10 ns, Figure 3.7a), and the PEGylated GO systems showing a slower equilibration of
the DOX adsorption (>20 ns for both systems, Figure 3.7a). Superimposed snapshots of the DOX
molecular positions in the different drug/nanocarrier systems at different initial, intermediate, and
final simulation times are shown in Figure 3.7b. While about 100% of the DOX molecules are
adsorbed on the accessible GO surface in the DOX/GO system, only about 80% and 60% of the
DOX molecules are adsorbed on the accessible GO surface in the DOX/Sh-PEGylated GO and
DOX/L-PEGylated GO systems, respectively.
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a)

b)
Figure 3.7. a) Number of adsorbed DOX molecules on the accessible GO surface in different
drug/nanocarrier systems as a function of simulation time; b) Superimposed snapshots of the DOX
molecules in different systems (Red = DOX/GO, Dark Yellow = DOX/Sh-PEGylated GO, Blue =
DOX/L-PEGylated GO) at different simulation times (GO sheets, PEG chains, and water
molecules are not shown).
The average total accessible GO surface for drug adsoprtion can be obtained by tracking the
GO-PEG contact area as a function of simulation time (Figure 3.8a). Given the fast equilibration
of the PEG chain configurations around the GO surface (Figure 3.6), an average contact area of
about 2,000 Å2 for the Sh-PEGylated GO nanocarrier and 2,800 Å2 for the L-PEGylated GO
nanocarrier (Figure 3.8a), signifies that about 70% of the GO surface for the former and 60% of
the GO surface for latter nanocarrier is accesible for the DOX adsorption. In the above calculations
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of the accessible GO surface, a value of 6,850 Å2 was considered for the SASA of GO. The PEGGO contact area for both systems remained constat during the simulation, indicating that the
adsorption of DOX molecules on the GO surface GO did not affect the PEG-GO contact area.
Similar dynamic contact area data were generated for the GO-DOX, DOX-PEG, and DOX-DOX
complexes in the different drug/nanocarrier systems (Figures 3.8b-3.8d). A larger average GODOX equilibrium contact area than those of the DOX/PEGylated GO systems (Figure 3.8b) is
directly correlated with the DOX adsorption data on the accesible GO surface given in Figure 3.7a.
Fluctuation of the DOX-PEG contact area in the DOX/L-PEGylated GO system at equilibrium
simulation times (Figure 3.8c) suggests that the DOX molecules tend to be more mobile around
the PEG chains, similar to the observation made based on the DOX RMSD data in Figure 5c.
Moreover, a comparison between the average water density in the hydration layer surrounding the
nanocarriers (Table 3-2) suggests that the DOX adsorption rate (Figure 3.7a) and evolution of GODOX contact area (Figure 3.8b) should be slower for the DOX/PEGylated GO systems, bacause
of a larger average water density in the hydration layer in these systems compared to that in the
DOX/GO system.
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a)

b)

c)

d)

Figure 3.8. Contact area for a) GO-PEG, b) GO-DOX, c) DOX-PEG, and d) DOX-DOX molecular
assemblies in the different drug/nanocarrier systems.
The average DOX-DOX equilibrium contact area (Figure 3.8d) may be used as a metric for DOX
aggregation in the different systems. A smaller average DOX-DOX contact area in the DOX/GO
system signifies less aggregation of the drug molecules in this system, while the level of DOX
aggregation is slightly higher for the PEGylated GO systems. A visual representation of the DOX
aggregation is given in Figure 3.2.
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3.5.Conclusions
There is an extensive body of evidence that PEGylation of graphene oxide (GO)
nanocarriers for anticancer drug delivery is an efficient way to improve the drug circulation time
and its delivery and targeting. While previous work has revealed critical aspects of the GO
PEGylation, the effect of PEG chain size on the loading dynamics and equilibration of a wellstudied anticancer drug, i.e., doxorubicin (DOX), has been overlooked. This is important as the
distribution of the adsorbed drug molecules on the accessible GO surface and PEG arms could
have implications for the delivery and targeting of the drug to a solid tumor site. In this
computational work, the relevant energetics and structural details of the DOX adsorption on
PEGylated GO systems are presented, revealing the mechanisms of drug adsorption as a function
of time and PEG chain length. Overall, there is a shift in the adsorption site for the drug molecules
from the accessible GO surface to the protruding PEG arms that can be attributed to a “water
barrier” effect in a hydration layer surrounding the nanocarriers. Interestingly, the total DOXnanocarrier interactions at equilibrium loading does not change appreciably going from GO to
PEGylated systems with different PEG chain lengths. Therefore, while drug loading energetics are
comparable in the different systems, a different distribution of the drug molecules on the
nanocarriers may have implications for their delivery in the human bloodstream, especially in the
presence of prevalent proteins in the blood such a human serum albumin.
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CHAPTER 4 DOXORUBICIN STABILITY AND RETENTION ON PEGYLATED
GRAPHENE OXIDE NANOCARRIERS IN THE PRESENCE OF HUMAN SERUM
ALBUMIN

4.1.Abstract
Drug retention on loaded nanocarriers during delivery to the action site is essential for maximizing
drug targeting and its therapeutic efficiency. In this work, molecular dynamics (MD) simulations
were performed to investigate the interactions between doxorubicin (DOX)-loaded graphene oxide
(GO) and PEGylated GO nanocarriers with human serum albumin (HSA), the most prevalent
protein in the human bloodstream and among the first to be adsorbed on the DOX-loaded
nanocarriers. The results indicate that drug stability and retention on PEGylated GO nanocarriers
are far more superior to the GO nanocarriers (control), consistent with the experimental findings
on the “stealth” characteristics of the PEGylated GO drug delivery systems. It is also demonstrated
in this work that the PEGylated GO nanocarriers retain the DOX molecules irrespective of the
HSA Sudlow site I and II orientations, thereby revealing their robustness in DOX loading. An
increased retention of the DOX molecules translates into its longer circulation time, which is
beneficial in drug targeting.
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4.2.Introduction
Intensive research in the field of nanotechnology-enabled drug delivery systems in the past
few years has brought graphene oxide (GO), a two-dimensional nanomaterial with unique
properties such as high surface area, water solubility, biofunctionality, and high drug loading
capacity into the spotlight.126–129 Reports have been published on the use of GO as a potential
nanocarrier for anticancer drugs in cancer treatment. GO nanosheets have been shown to be
efficient in loading a large number of drug molecules on their accessible surfaces and edges
through π-π interactions, hydrogen bonds, and/or electrostatic interactions.8,9,127,130 In this respect,
the tumor-targeting and drug release mechanisms in GO-based drug delivery systems using
different intrinsic or extrinsic stimuli have been broadly investigated.90 For example, it has been
shown that GO can release the loaded drug molecules at an acidic pH level, which is characteristic
of a solid tumor.
Although GO-based drug delivery systems possess adequate drug loading and release
characteristics, their stability in the presence of proteins prevalent in the human bloodstream
should not be overlooked. Drug retention on nanocarriers while been carried to the action site is
reflected in the drug circulation time, and a low level of premature drug release is essential for
achieving acceptable drug targeting and therapeutic efficiency. This is especially true for
noncovalently-bound drug delivery systems, where the drug molecules are physically adsorbed on
the nanocarrier surfaces.105 As a potential remedy to improve the drug retention on GO
nanocarriers, as well as to increase their biocompatibility, covalent bonding method may be
pursued. In this method, polymer chains, such as poly(ethylene glycol) (PEG), are grafted on the
GO nanocarrier surface. PEG has low toxicity, good biocompatibility and protein resistance, as
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well as high solubility in water and, therefore, is widely used for the surface modification of
nanoparticles in biological applications.131 “PEGylation” of nanoparticles adds “stealth”
characteristics to them, thereby prolonging the drug circulation time.132 Many researchers have
published reports on the use of PEGylated GO in biological applications. For example, Xu et al.110
used six-armed PEG chains to modify the GO sheet as a drug nanocarrier, which was used to
deliver paclitaxel (PTX), a low water-soluble drug. PTX-loaded PEGylated GO exhibited a higher
cytotoxicity effect compared to free PTX. In another study, Yin et al.133 functionalized GO with
folic acid/PEG to deliver siRNA for pancreatic cancer therapy, since it showed better
biocompatibility and stability in solution.
In this study, we investigated the stability of the doxorubicin (DOX)-loaded GO and
PEGylated GO systems with different PEG chain lengths in the presence of human serum albumin
(HSA), the most abundant protein in the human blood plasma,134 using molecular dynamics (MD)
simulation. A molecular level understanding of the interactions of a drug delivery system with
HSA is very important, as HSA is among the first proteins to be adsorbed on the drug delivery
system.135 This protein, which is helical with turns and extended loops and resembles a heart
shape,136 has been widely used to model the protein-substrate interactions. It contains three
domains, designated as I, II and III.136,137 Each domain has two subdomains, labeled A and B. This
structural classification may be considered a functional categorization, since subdomains are
responsible for binding with different ligand types. HSA is one of the main transporter proteins in
the human blood plasma with a large number of sites to bind many ligands with different chemical
structures.22 Previous studies have shown that there are two main drug binding sites on HSA, which
are known as Sudlow sites138 and are located in Subdomains IIA and IIIA. Because of high
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concentration in the human blood plasma and presence of many binding pockets, HSA is a good
model to investigate the stability of a drug delivery system in this work. Vilhena et al.22 studied
the adsorption of bovine serum albumin (BSA) on the graphene surface and the resulting structural
changes of the protein using free and forced adsorption protocols. Their results indicated that BSA
is able to preserve the structural properties of most of the binding sites. Other researchers have
also explored the interactions of serum albumin with pristine graphene or GO.139–141 However, to
the best of our knowledge, the behavior of drug-loaded GO and PEGylated GO in the presence of
HSA have not been investigated in molecular detail. Ideally, the HSA adsorption on drug-loaded
nanocarriers should not lead to the premature drug release while been carried to the action site.
The computational results presented in this work reveal the underlying mechanisms of the HSAnanocarrier interactions toward a better understanding of the GO PEGylation effect on the drug
stability and retention on the nanocarrier.

4.3.Computational Method
All chemical structures of GO, PEGylated GO, and DOX, were built in BIOVIA Materials
Studio (v8.0). The surfaces of pristine graphene sheets (size: 40×40 Å2) were randomly decorated
on both sides with hydroxyl (-OH) and epoxide (-O) functional groups,99,111,112 while carboxylic
acid groups (-COOH) were added to the edges of the sheets.47,99,111–113 The final GO structure is
represented by C10O1(OH)1(COOH)0.5.113 The protonation states of the functional groups were set
according to the physiological pH of 7.4, similar to our previous work.142 Six chains of short PEG
(molecular length corresponding to 15 monomers) were covalently attached to both sides of the
GO sheet, yielding the short-PEGylated GO nanocarrier structure (labeled as Sh-PEGylated GO).47
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In each chain, the amide linkage was replaced with a carboxyl group on the GO sheet.107 Longer
PEG chains (molecular length corresponding to 30 monomers) were further used to model the
long-PEGylated GO (L-PEGylated GO) nanocarrier structure. The resulting models were
geometry-optimized using the Dreiding force field114 and charge-equilibrated using the Gasteiger
charges routine.113 The equilibrium structures were next exported to the Visual Molecular
Dynamics (VMD) software,115 placed in a simulation cell, and packed with TIP3P water
molecules.116 To equilibrate the PEG chain conformations on the GO sheets, dynamic simulations
were run for 20 ns using the NPT ensemble at 310 K (normal human body temperature) and 1 atm
in the NAMD (v2.12) software package.117 The force field parameters for GO and PEGylated GO
were extracted from CHARMM36, similar to the study by Luo et al.47 The force field parameters
and topology of the DOX molecule were obtained from the SwissParam server.143 For all
simulations in this work, the NAMD software package with CHARMM36 force field was used.
Also, the time step, cut-off distance for long-range interactions, and switch distance for short-range
interactions were set to 2 fs, 12 Å, and 10 Å, respectively.
Once the equilibrated GO and PEGylated GO structures were obtained, three drug delivery
systems, i.e., DOX/GO, DOX/Sh-PEGylated GO, and DOX/L-PEGylated GO, were built, where
the nanocarrier was placed in the middle of a simulation cell, surrounded by 10 DOX molecules
(evenly placed on both sides of the nanocarrier with five drugs on each side at an initial distance
of 15 Å) and TIP3P water molecules116 that were packed around the drug/nanocarrier complexes.
The solvated drug delivery systems were neutralized by adding Na+ cations to the systems. NPT
simulations were next run on the systems for 30 ns to load the drug molecules on the nanocarriers.
The equilibrium structures of the DOX-loaded nanocarriers in the aqueous medium were next
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extracted and brought in contact with an HSA protein to build the initial structures for this
investigation. For this purpose, the HSA crystal structure was extracted from the Protein Data Bank
(PDB ID: 1AO6).136 The protonation state of the protein was then set according to pH of 7.4, as
was done for the nanocarrier systems. The net charges of the protein in this state were -15e.144 The
HSA protein was next placed on top of the drug-loaded nanocarriers in two different orientations.
Structural studies have shown that there are two primary drug binding sites on the HSA, which are
known as Sudlow sites I and II.137 In this work, the two protein orientations relative to the
nanocarrier surfaces were selected so that in one orientation (labeled Orientation 1), the HSA
Sudlow sites are directly facing the nanocarrier surface and in the other (Orientation 2), the sites
are away from it (180° rotation around the axis of the protein parallel to the nanocarrier surface).
These same orientations were used in a similar study by Vilhena et al.22 In all drug delivery
systems, the distance between the protein center of mass and the GO surface was set to 38 Å. Once
the HSA protein was brought in contact with the DOX-loaded nanocarriers, the TIP3P water
molecules were packed around the HSA/DOX/nanocarrier complexes similar to the procedure
mentioned above. Next, Na+ cations and Cl- anions were added to neutralize the systems with the
NaCl concentration set to 0.15 mol/L.145 Structural details of the six HSA/DOX-loaded nanocarrier
systems are given in Table 1. Also, snapshots of the initial structures of the different systems are
shown in Figure 1.
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Table 4-1 – Structural details of the HSA/DOX-loaded nanocarrier systems
System
DOX/GO
DOX/Sh-PEGylated-GO
DOX/L-PEGylated-GO

Orientation
1
2
1
2
1
2

Number of Molecules
HSA Nanocarrier DOX Water
1
1
10
27,242
1
1
10
26,650
1
1
10
26,628
1
1
10
26,062
1
1
10
27,092
1
1
10
26,404

Cell Size
(Å3)
94×101×106
94×101×104
94×102×105
92×98×100
94×102×107
94×101×105

Figure 4-1 Initial snapshots of the doxorubicin (DOX)-loaded GO and PEGylated GO
systems with short (Sh-PEGylated GO) and long PEG chains (L-PEGylated GO) in the presence
of human serum albumin (HSA) in two different orientations, where the HSA’s Sudlow binding
sites I and II are directly facing the nanocarrier (Orientation 1) or away from it (Orientation 2).
The aqueous medium (not shown) has a physiological pH of 7.4.

55

The systems underwent a 5,000-step energy minimization, after which NPT simulations were
run for 300 ns. The system temperature and pressure were kept constant at 310 K and 1 atm during
simulation using a Langevin thermostat and barostat, respectively.119 The electrostatic interactions
were handled by the particle mesh Ewald (PME) method.62
Post-processing of the trajectory files included the calculation of the following metrics: 1)
DOX-GO, and DOX-HSA total interaction energies, 2) root mean square deviations (RMSDs) of
the protein and DOX molecules relative to their initial structures,142 3) DOX-HSA contact areas in
different HSA orientations,142 and 4) histograms for the DOX interactions with the HSA protein
residues during the last 100 frames of the simulation. It is noteworthy to mention that HSA has
585 residues.146,147

4.4.Results and Discussion
The total DOX-nanocarrier interaction energies as a function of simulation time and
orientation of the HSA protein are shown in Figure 2. Here, the interaction energies are divided
into the DOX-GO interactions, i.e., interactions between the DOX molecules and the GO surface
of the nanocarriers (Figures 2a-2c), and the DOX-PEG interactions, which are indicative of the
interactions between the DOX molecules and the PEG arms of the PEGylated GO nanocarriers
(Figure 2d). With an increase in the contact time between the DOX-loaded nanocarriers and the
HSA protein (especially toward the longer simulation times), the DOX-GO interaction energy in
the DOX/GO system becomes increasingly more positive for Orientation 1, as well as for
Orientation 2 (after an initial strengthening of the interactions) (Figure 2a). This signifies either
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the DOX molecules collectively moving away from the surface toward the HSA protein or release
of at least one drug molecule and its pick-up by the HSA protein. The latter point is confirmed by
investigating the time-varying RMSD data in Figure 3. Somewhere around 100 ns for Orientation
1 and 30 ns for Orientation 2, one DOX molecule for the former and two DOX molecules for the
latter are seen to be unloaded from the GO surface in the DOX/GO system (Figure 4). The
remainder of the DOX molecules are evenly spread over the GO surface, while their large RMSD
values signify their moving away from the surface. On the contrary, the DOX-GO interactions in
the PEGylated GO systems exhibit a slight increase (more negative interaction energies) with time
(Figure 2b and 2c). Interestingly, this behavior is consistent for both DOX/Sh-PEGylated GO and
DOX/L-PEGylated GO systems, irrespective of the HSA protein orientation. On average, the
DOX-PEG interaction energies remain constant for both HSA orientations with time (Figure 2d).
Similarly, the RMSD data for the PEGylated systems show high retention of the DOX molecules
on these nanocarriers (Figure 3). The nearly constant RMSD values for the PEGylated systems up
to long simulation times signifies essentially no drug release in these systems when in contact with
the HSA protein, except for the Sh-PEGylated system in Orientation 2 of the HSA protein above
280 ns (Figure 3b). So, while the orientation independence of the drug-loaded nanocarrier-HSA
interactions and the resulting drug retention on the nanocarrier are greatly increased by the
PEGylation of the GO, the effects become more pronounced with an increase in the PEG chain
length.
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Figure 4-2 – Total interaction energy between the DOX molecules and the GO surface in
a) DOX/GO, b) DOX/Sh-PEGylated GO, and c) DOX/L-PEGylated GO systems, as well
between the DOX molecules and the PEG chains in d) DOX/PEGylated GO systems (with
short and long PEG chain lengths) as a function of simulation time and orientation of the
HSA protein relative to the GO surface.
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)
Figure 4-3 Root mean square deviation (RMSD) of the DOX molecular positions relative
to their initial positions in the different DOX/nanocarrier systems as a function of
simulation time with the HSA protein in a) Orientation 1 and b) Orientation 2.

Figure 4-4 Schematics of the released DOX molecules from the DOX-loaded GO
nanocarriers in the presence of the HSA protein in different orientations during
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The DOX-HSA interaction energies in the different DOX-loaded systems and HSA
orientations are shown in Figure 5. While the PEGylated systems exhibit a stable and nearly
constant DOX-HSA interactions over the course of the simulation in both HSA orientations, in the
DOX/GO system, the DOX molecules show a sudden increase in the DOX-HSA attraction (more
negative interaction energy) by an average value of about -200 kcal/mol at around 100 ns of
simulation for Orientation 1 (Figure 5a). This is consistent with the observation made for the DOXGO interactions in Orientation 1, where a sudden average change of about +200 kcal/mol occurs
at around 100 ns (Figure 2a). Therefore, the released DOX molecules from the GO surface are
essentially picked up by the HSA protein. Again, the DOX molecular retention on the PEGylated
GO nanocarriers are more pronounced than that of the GO nanocarrier for both HSA orientations.

)
Figure 4-5 Total interaction energy between the DOX molecules and the HSA protein as a
function of simulation time with the HSA protein in a) Orientation 1 and b) Orientation 2.
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To gain a clearer picture of the DOX-HSA interactions, the instantaneous DOX-HSA contact
area and average number of HSA residues in contact with the DOX molecules during the last
200 ns of simulation are shown in Figure 6 and Table 2, respectively. The larger average number
of HSA residues in contact with the GO nanocarrier (in both HSA orientations) compared to the
PEGylated GO nanocarriers indicates, once again, the larger propensity of the DOX molecules to
be released from the GO nanocarrier in the presence of HSA.

)
Figure 4-6 Contact area between the DOX molecules and the HSA protein as a function of
simulation time with the HSA protein in a) Orientation and b) Orientation 2.
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Table 4-2 Average number of HSA protein residues in contact with the DOX molecules during
the last 200 ns of the simulation
Orientation
1
2

System

Average Number of
HSA Residues

DOX/GO
DOX/Sh-PEGylated-GO
DOX/L-PEGylated-GO
DOX/GO
DOX/Sh-PEGylated-GO
DOX/L-PEGylated-GO

24
6
13
30
18
8

The near-equilibrium distribution of the frequencies of the DOX molecular contact with the
individual HSA residues (Figure 7) reveals that the DOX molecules are more “dispersed” in their
contact with the HSA protein, while in the PEGylated systems, some level of drug aggregation is
evident.
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)

Figure 4-7– Histograms depicting the contact frequency of the DOX molecules with the HSA
protein residues (residue numbers from 1-585) during the last 100 frames of the simulation.
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4.5.Conclusions
In this computational investigation, the effect of PEGylation of graphene oxide (GO)
nanocarriers for doxorubicin (DOX) on the drug stability and retention in the presence of human
serum albumin (HSA) was studied. Using the DOX-GO and DOX-HSA total interaction energies
as metrics, it was revealed that DOX is more prone to premature release from the GO nanocarrier
than the PEGylated GO. Since the HSA protein has two main binding sites for the drug, an
investigation into the orientation dependence of the drug release in the GO nanocarrier revealed
that the drug release is more pronounced if the binding sites are farther away from the GO surface.
Clearly, there is an orientation dependence of the DOX release in the GO nanocarrier. On the
contrary, the PEGylated GO nanocarrier shows a remarkable DOX retention characteristics that
are independent from the HSA orientation. Furthermore, the extent of drug retention on the
PEGylated GO nanocarriers gets larger as the PEG chain length increases.
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CHAPTER 5 CONCLUSION
In this work, graphene oxide (GO) was computationally investigated as a potential drug
nanocarrier for doxorubicin (DOX). The effect of environmental pH level, oxidation density of the
GO nanosheet, and PEG chain length on the drug loading, release, and retention was explored. The
ability of the nanocarrier toload the drug at pH 7 and to release it at pH 5 was disscussed. Finally,
the drug stabality and retention on PEGylated GO nanocarriers in the presence of human serum
albumin (HSA) was investigated.
The computational results reveled that the adsorption of the DOX molecules on the GO
surface increases with an increase in the GO surface oxygen density, except for the highest O/C
ratio of 1:3. The effect of pH was found to be negligible at neutral and acidic pH levels, but
significantly strong interactions were observed for the DOX/GO combination at lower surface
oxygen density (O/C ratio of 1:6) and basic pH levels.
To investigate the ability of the drug delivery systems to load the DOX molecules at pH 7
and releasing at pH 5, the interaction energy of the DOX/GO surface was calculated, and it was
shown that GO can release DOX molecules at acidic pH levels. Introducing PEG chains on the
GO surface changed the drug adsorption mechanism on the GO nanosheets. DOX molecules tend
to be adsorbed on the accessible surface of the GO rather than the part occupied by the PEG chains.
However, by increasing the PEG chain length, some drug molecules are adsorbed on the PEG
arms.
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The last part of the study revealed that the DOX-loaded PEGylated GO systems are more
stable in the presence of HSA than DOX-loaded GO system. HSA caused a premature release of
some DOX molecules from the GO surface in the DOX-loaded GO system. However, nearly all
DOX molecules were retained on the PEGylated GO systems.
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CHAPTER 6 FUTURE WORK
One complementary investigation recommended for future work is to explore the DOX
release from the drug-loaded GO and PEGylated GO nanocarriers in the presence of HSA as the
pH level drops to acidic. This would be reminescent of the arrival of the drug-loaded nanocarrier
to the tumor site.
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APPENDIX A: A sample configuration file to run the DOX/Sh-PEGylated GO system on
NAMD
#############################################################
## JOB DESCRIPTION
##
#############################################################
# Minimization and Equilibration of
# Ubiquitin in a Water Box
#############################################################
## ADJUSTABLE PARAMETERS
##
#############################################################
structure
coordinates

../common/ShpegDOX_ionized.psf
../common/ShpegDOX_ionized.pdb

set temperature
set outputname
firsttimestep

310
ShpegDOX1
0

#############################################################
## SIMULATION PARAMETERS
##
#############################################################
# Input
paraTypeCharmm
on
parameters
../common/par_all36_prot.prm
mergeCrossterms
yes
parameters
../common/par_all36_lipid.prm
parameters
../common/par_all36_carb.prm
parameters
../common/par_all36_cgenff.prm
parameters
../common/DOX.par
parameters
../common/DOX_Protonated.par
parameters
../common/par_all36_cgenff_vega.inp
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parameters
parameters
temperature

../common/M5_Peggo_mis.inp
../common/toppar_water_ions_namd.str
$temperature

# Force-Field Parameters
exclude
scaled1-4
1-4scaling
1.0
cutoff
12.0
switching
on
switchdist
10.0
pairlistdist
14.0
# Integrator Parameters
timestep
2.0 ;# 2fs/step
rigidBonds
all ;# needed for 2fs steps
nonbondedFreq
1
fullElectFrequency 2
stepspercycle
10
# Constant Temperature Control
langevin
on ;# do langevin dynamics
langevinDamping 1 ;# damping coefficient (gamma) of 1/ps
langevinTemp
$temperature
langevinHydrogen off ;# don't couple langevin bath to hydrogens
# Periodic Boundary Conditions
cellBasisVector1 74.813 0.0 0.0
cellBasisVector2 0.0 69.809 0.0
cellBasisVector3 0.0 0 94.504
cellOrigin
26.721588134765625 38.92574691772461 32.887550354003906
wrapAll

on

# PME (for full-system periodic electrostatics)
83

PME
yes
PMEGridSpacing
1.0
#manual grid definition
#PMEGridSizeX
45
#PMEGridSizeY
45
#PMEGridSizeZ
48
# Constant Pressure Control (variable volume)
useGroupPressure yes ;# needed for rigidBonds
useFlexibleCell
no
useConstantArea
no
langevinPiston
on
langevinPistonTarget 1.01325 ;# in bar -> 1 atm
langevinPistonPeriod 100.0
langevinPistonDecay 50.0
langevinPistonTemp $temperature
# Fixed Atoms Constraint (set PDB beta-column to 1)
if {1} {
fixedAtoms
on
fixedAtomsFile ../common/fixgo.pdb
fixedAtomsCol
B
}
# Output
outputName

$outputname

restartfreq
25000 ;# 500steps = every 1ps
dcdfreq
10000
xstFreq
2500
outputEnergies
2500
outputPressure 2500
outputTiming
25000
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#############################################################
## EXTRA PARAMETERS
##
#############################################################
#############################################################
## EXECUTION SCRIPT
##
#############################################################
# Minimization
minimize
1000
reinitvels
$temperature
run 10000000 ;# 20ns
APPENDIX B: A sample script to calculate the contact area of DOX and PEG chain in
DOX/Sh-PEGylated GO

Note: A part of script that calculate SASA is extracted from the script written by Sajad Falsafi
and Zahra Karimi
puts -nonewline "\n \t \t Selection: "
#gets stdin selmode
# selection
set dox [atomselect top "resname LIG"]
set peg [atomselect top "resname peg"]
set pegdox [atomselect top "resname LIG or resname peg"]
set n [molinfo top get numframes]
set output [open "SASA_DOXpeg_shpeg4.dat" w]
# sasa calculation loop
for {set i 0} {$i < $n} {incr i} {
molinfo top set frame $i
set sasa [expr ([measure sasa 1.4 $dox]+[measure sasa 1.4 $peg]-[measure sasa 1.4
$pegdox])*0.5]
puts "\t \t progress: $i/$n"
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puts $output "$sasa"
}
puts "\t \t progress: $n/$n"
puts "Done."
puts "output file: SASA_DOXpeg_shpeg4.dat"
close $output
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APPENDIX C: Parameter file of DOX molecule used in this study

* ---* Built parameters for DOX.mol2
* by user vzoete Thu Dec 14 18:05:51 CET 2017
* ---*
BONDS
CR CR 306.432 1.5080
CR HCMM 342.991 1.0930
CR NR 365.876 1.4510
CR OR 363.214 1.4180
CB CB 401.068 1.3740
CB HCMM 381.853 1.0840
CB OR 404.019 1.3760
CB C=O 322.985 1.4570
C=O O=C 931.963 1.2220
CB CR 356.737 1.4860
CR C=O 301.539 1.4920
OR HOR 560.905 0.9720
OR HOCC 564.143 0.9730
NR HNR 467.061 1.0190
ANGLES
CB CB CB 48.145 119.9770
CB CB HCMM 40.517 120.5710
CB CB OR 69.663 116.4950
CB CB C=O 57.429 114.4750
CB CB CR 57.788 120.4190
CR CR CR 61.243 109.6080
CR CR HCMM 45.770 110.5490
HCMM CR HCMM 37.134 108.8360
CR CR NR 55.917 108.2900
NR CR HCMM 46.994 110.2970
CR CR OR 71.390 108.1330
OR CR HCMM 56.205 108.5770
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CR OR CR 86.143 106.9260
CB C=O CB 67.144 115.5660
CB C=O O=C 52.823 119.9680
CB CR CR 54.406 108.6170
CB CR HCMM 45.122 109.4910
CR CR C=O 55.917 107.5170
C=O CR OR 37.998 104.1120
CB CR OR 63.186 107.9780
CR C=O CR 82.832 118.0160
CR C=O O=C 67.504 124.4100
C=O CR HCMM 46.778 108.3850
CR OR HOR 57.069 106.5030
CB OR CR 77.363 102.8460
CB OR HOCC 52.247 105.4090
OR CR OR 83.192 111.3680
CR NR HNR 54.910 109.0620
HNR NR HNR 42.820 105.9980
DIHEDRALS
CB CB CB CB
3.500 2 180.00
CB CB CB HCMM 3.500 2 180.00
CB CB CB C=O
3.500 2 180.00
CB CB C=O CB
1.250 2 180.00
CB CB C=O O=C 1.128 2 180.00
CB CB CB OR
3.500 2 180.00
CB CB OR CR
2.191 2 180.00
CB OR CR HCMM 0.053 3 0.00
CB CB CB CR
3.500 2 180.00
CB CB OR HOCC 1.401 2 180.00
CB CB CR CR
0.225 2 180.00
CB CB CR OR
0.075 3 0.00
CB CB CR HCMM -0.210 2 180.00
CB CB CR HCMM 0.196 3 0.00
CB CR CR CR
0.150 3 0.00
CB CR CR HCMM 0.195 3 0.00
CB CR OR CR
0.100 3 0.00
CB CR CR C=O
0.150 3 0.00
CB CR CR OR
0.150 3 0.00
CR CR CR CR
0.051 1 0.00
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CR CR
CR CR
CR CR
CR CR
CR CR
CR CR
CR CR
CR CR
CR CR
CR CR
CR CR
CR CR
CR CR
CR CR
CR CR
CR CR
CR CR
CR CR
CR CR
CR OR
CR OR
CR OR
CR OR
CR OR
CR OR
OR CR
OR CR
OR CR
OR CR
OR CR
OR CR
C=O CB
C=O CB
C=O CB
CR CB
CR CB
CR CR
CR CR
CR CR

CR CR
0.341 2 180.00
CR CR
0.166 3 0.00
CR OR -0.344 1 0.00
CR OR
0.879 2 180.00
CR OR
0.238 3 0.00
CR HCMM 0.320 1 0.00
CR HCMM -0.315 2 180.00
CR HCMM 0.132 3 0.00
NR HNR -0.214 1 0.00
NR HNR 0.162 2 180.00
NR HNR 0.140 3 0.00
OR CR -0.341 1 0.00
OR CR
0.378 2 180.00
OR CR
0.378 3 0.00
OR HOR 0.135 2 180.00
OR HOR 0.118 3 0.00
CR NR -0.710 1 0.00
CR NR -0.046 2 180.00
CR NR
0.550 3 0.00
CR OR
0.115 1 0.00
CR OR -0.355 2 180.00
CR OR
0.361 3 0.00
CR HCMM 0.285 1 0.00
CR HCMM 0.160 2 180.00
CR HCMM 0.285 3 0.00
CR OR
0.204 1 0.00
CR OR
0.699 2 180.00
CR OR
0.480 3 0.00
CR HCMM -0.327 1 0.00
CR HCMM 0.536 2 180.00
CR HCMM 0.140 3 0.00
CB HCMM 1.000 2 180.00
CB C=O
1.000 2 180.00
CB OR
1.000 2 180.00
CB CR
3.500 2 180.00
CB OR
3.500 2 180.00
C=O CR
0.051 1 0.00
C=O CR
0.088 2 180.00
C=O CR
0.273 3 0.00
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CR CR C=O O=C 0.412 1 0.00
CR CR C=O O=C 0.070 2 180.00
CR CR C=O O=C
0.163 3 0.00
CR C=O CR OR
0.275 3 0.00
CR C=O CR HCMM -0.036 1 0.00
CR C=O CR HCMM 0.043 2 180.00
CR C=O CR HCMM 0.266 3 0.00
CR CR CR C=O
0.033 1 0.00
CR CR CR C=O -0.078 2 180.00
CR CR CR C=O
0.071 3 0.00
C=O CR CR HCMM -0.128 1 0.00
C=O CR CR HCMM 0.029 2 180.00
C=O CR OR HOR -0.826 1 0.00
C=O CR OR HOR -0.830 2 180.00
C=O CR OR HOR
0.141 3 0.00
O=C C=O CR OR -0.198 1 0.00
O=C C=O CR OR
0.365 2 180.00
O=C C=O CR OR -0.070 3 0.00
O=C C=O CR HCMM 0.330 1 0.00
O=C C=O CR HCMM -0.704 2 180.00
O=C C=O CR HCMM 0.154 3 0.00
OR CB CB HCMM 3.500 2 180.00
NR CR CR HCMM -0.372 1 0.00
NR CR CR HCMM -0.617 2 180.00
NR CR CR HCMM 0.169 3 0.00
NR CR CR OR
0.150 3 0.00
HCMM CR CR HCMM 0.142 1 0.00
HCMM CR CR HCMM -0.693 2 180.00
HCMM CR CR HCMM 0.157 3 0.00
HCMM CR NR HNR -0.076 1 0.00
HCMM CR NR HNR -0.220 2 180.00
HCMM CR NR HNR 0.178 3 0.00
HCMM CR OR HOR 0.298 1 0.00
HCMM CR OR HOR -0.138 2 180.00
HCMM CR OR HOR 0.173 3 0.00
HCMM CB CB HCMM 3.500 2 180.00
IMPROPER
CB CB CB HCMM

1.079 0

0.00
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CB CB CB OR
3.454 0 0.00
CB CB CB C=O
1.943 0 0.00
C=O CB CB O=C 9.356 0 0.00
CB CB C=O CB
1.943 0 0.00
CB CR CB CB
2.879 0 0.00
CB CB CB CR
2.879 0 0.00
CR CR CB HCMM 0.000 0 0.00
CR C=O CR OR
0.000 0 0.00
CR C=O CR CR
0.000 0 0.00
C=O CR CR O=C 10.507 0 0.00
CR OR C=O HCMM 0.000 0 0.00
CR CR CB OR
0.000 0 0.00
CR OR OR CR
0.000 0 0.00
CR CR OR HCMM 0.000 0 0.00
CR CR CR HCMM 0.000 0 0.00
CR CR CR NR
0.000 0 0.00
CR CR CR OR
0.000 0 0.00
CR OR CR CR
0.000 0 0.00
CR OR CR HCMM 0.000 0 0.00
CR HCMM CR HCMM 0.000 0 0.00
NR HNR CR HNR 0.000 0 0.00
CR HCMM OR HCMM 0.000 0 0.00
NONBONDED nbxmod 5 atom cdiel shift vatom vdistance vswitch cutnb 14.0 ctofnb 12.0 ctonnb 10.0 eps 1.0 e14fac 1.0 wmin 1.5
CB 0.000000 -0.070000 1.992400
CR 0.000000 -0.055000 2.175000 0.000000 -0.010000 1.900000
OR 0.000000 -0.152100 1.770000
C=O 0.000000 -0.110000 2.000000
O=C 0.000000 -0.120000 1.700000 0.000000 -0.120000 1.400000
NR
0.000000 -0.200000 1.850000
HCMM 0.000000 -0.022000 1.320000
HOR 0.000000 -0.046000 0.224500
HOCC 0.000000 -0.046000 0.224500
HNR 0.000000 -0.046000 0.224500
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